Cell therapy weekly: US FDA rejects Mesoblast’s lead allogeneic cell therapy candidate

Written by RegMedNet

This week: the US FDA has rejected Mesoblast’s lead allogeneic cell therapy candidate for SR-aGVHD, the European Medicines Agency has approved an investigational gene therapy for cerebral adrenoleukodystrophy, a strategic partnership is announced to develop a GMP-compliant device for high-throughput stem cell encapsulation, and the ALLOB allogeneic bone cell therapy platform receives an exclusive license agreement for development and commercialization in China and Southeast Asia. The news highlights: US FDA rejects Mesoblast’s lead allogeneic cell therapy candidate for SR-aGVHD Investigational gene therapy receives EMA approval for cerebral adrenoleukodystrophy Expanded partnership aims to develop a GMP-compliant device for high-throughput stem cell...

To view this content, please register now for access

It's completely free